Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 1, 2026Technology in Cancer Research & TreatmentOpen Access

Isolation of Novel Fully Human Single-Domain Antibodies Targeting GUCY2C from a Heavy-Chain-Only Transgenic Mouse Platform

View Full Paper
Ask AI
Bookmark
Share

Authors

PZPingxia ZhuLHLei HeXDXiaoming Du

Discussion

Loading...

Member takes

Overview

Laboratory study demonstrates efficient generation of high-affinity fully human single-domain antibodies targeting GUCY2C using transgenic mice, suggesting promise for CAR-T drug development.

Key Points

  • Develop and characterize fully human single-domain antibodies targeting the tumor antigen guanylyl cyclase C using a heavy-chain-only transgenic mouse platform.
  • Immunized transgenic huNano mice with recombinant guanylyl cyclase C protein to induce heavy-chain-only antibody production.
  • Selected antigen-specific single-domain antibody sequences via phage display and expressed them in mammalian expression vectors.
  • Assessed binding affinity, thermal stability, and aggregation using ELISA, flow cytometry, biolayer interferometry, and size-exclusion chromatography.
  • Obtained multiple single-domain antibodies displaying specific guanylyl cyclase C recognition and strong binding affinities.
  • Achieved monomeric purity exceeding 95% with aggregate levels below 5% following single-step purification.
  • Demonstrated favorable thermal stability profiles, with melting temperatures and aggregation onset temperatures spanning 60 °C to 68 °C.

Cite This Study

Zhu et al. (2026) studied this question.

synapsesocial.com/papers/6aa928f2a9624f76b4cdc32dhttps://doi.org/10.1177/15330338261473054
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 6361: KY-HC-mouse: A low-cost and rapid nanobody discovery platform2024
  2. 2Abstract 1647: RenNano platform enables efficient discovery of fully human VHH antibodies2026
  3. 3Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only2000 · 61 citations
  4. 4Computational refinement and multivalent engineering of complementarity-determining region-grafted nanobodies on a humanized scaffold for retaining antiviral efficacy2025
  5. 5Abstract 5333: NeoMab: A novel platform for fully human therapeutic antibody development2024